Expression of Endothelin-A-Receptor predicts unfavourable response to neoadjuvant chemotherapy in locally advanced breast cancer

British Journal of Cancer

Volumn 91, Issue 3, 2004, Pages 434-440

  Wulfing P ^a   Tio, J ^a,b   Kersting, C ^a   Sonntag, B ^a   Buerger, H ^a   Wulfing C ^a   Euler, U ^b   Boecker, W ^a   Tulusan, A H ^b   Kiesel, L ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b INSTITUTE OF PATHOLOGY   (Germany)

Author keywords

Chemoresistance; ETAR; ETBR ET 1; Immunohistochemistry; Preoperative

Indexed keywords

BIOCHEMICAL MARKER; CYCLOPHOSPHAMIDE; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; EPIRUBICIN; FLUOROURACIL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; METHOTREXATE; PACLITAXEL;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER TISSUE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOGISTIC REGRESSION ANALYSIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; TUMOR BIOPSY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DRUG RESISTANCE, NEOPLASM; ENDOTHELIN-1; EPIRUBICIN; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOADJUVANT THERAPY; PREDICTIVE VALUE OF TESTS; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 4143147684     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601889     Document Type: Article

References (37)

1. Alanen K, Deng DX, Chakrabarti S (2000) Augmented expression of endothelin-1, endothelin-3 and the endothelin-B receptor in breast carcinoma. Histopathology 36: 161-167
2. Ali H, Dashwood M, Dawas K, Loizidou M, Savage F, Taylor I (2000) Endothelin receptor expression in colorectal cancer. J Cardiovasc Pharm 36: S69-S71
3. Asham E, Shankar A, Loizidou M, Fredericks S, Miller K, Boulos PB, Burnstock G, Taylor I (2001) Increased endothelin-1 in colorectal cancer and reduction of tumor growth by ET(A)receptor antagonism. Br J Cancer 30: 1759-1763
4. Bagnato A, Catt KJ (1998) Endothelin as autocrine regulator of tumor cell growth. Trends Endocrinol Metab 9: 378-383
5. Bagnato A, Cirilli A, Salani D, Simeone P, Muller A, Nicotra MR, Natali PG, Venuti A (2002) Growth inhibition of cervix carcinoma cells in vivo by Endothelin A Receptor blockade. Cancer Res 62: 6381-6384
6. Bagnato A, Salani D, Di Castro V, Wu-Wong JR, Tecce R, Nicotra MR, Venuti A, Natali PG (1999) Expression of endothelin-1 and endothelin A receptor in ovarian carcinoma: evidence for an autocrine role in tumor growth. Cancer Res 59: 1-8
7. Bagnato A, Tecce R, Moretti C, Di Castro V, Spergel D, Catt KG (1995) Autocrine actions of ET-1 as a growth factor in human ovarian carcinoma cells. Clin Cancer Res 1: 1059-1066
8. Bek EL, McMillen MA (2000) Endothelins are angiogenic. J Cardiovasc Pharmacol 36: S135-S139
9. Del Bufalo D, Di Castro V, Biroccio A, Varmi M, Salani D, Rosano L, Trisciuglio D, Spinella F, Bagnato A (2002) Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for Akt activation. Mol Pharmacol 61: 524-532
10. Eberl LP, Egidy G, Pinet F, Juillerat-Jeanneret L (2000a) Endothelin receptor blockade potentiates FaslL-induced apoptosis in colon carcinoma cells via the protein kinase C-pathway. J Cardiovasc Pharmacol 36: S354-S356
11. Eberl LP, Valdenaire O, Saintgiorgio V, Jeannin JF, Juillerat-Jeanneret L (2000b) Endothelin receptor blockade potentiates FasL-induced apoptosis in rat colon carcinoma cells. Int J Cancer 86: 182-187
12. Euler U, Dresel V, Bühner M, Volkholz H, Tulusan AH (2002) Dose and time intensified epirubicin/cyclophosphamide (EC) as preoperative treatment in locally advanced breast cancer. Breast Cancer Res Treat 76(Suppl 1): S51
13. Ferlay J, Bray F, Pisani P, Parkin D, Globocan 2000 Cancer incidence, mortality and prevalence worldwide, Version 1.0. IARC Cancer BASE No. 5. IARC Press [monography] 2001. Available from http:// www-dep.iarc.fr/globocan/ globocan.html [accessed Dec 23, 2003]
14. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz Jr AB, Fisher ER, Wickerham DL, Wolmark N, DeCillis A, Hoehn JL, Lees AW, Dimitrov NV (1997) Effect of preoperative chemotherapy on loco-regional disease in women with operable breast cancer: findings from the National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15: 2483-2493
15. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz Jr AB, Hoehn JL, Lees AW, Dimitrov NV, Bear HD (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16: 2672-2685
16. Grant K, Loizidou M, Taylor I (2003) Endothelin-1: a multifunctional molecule in cancer. Br J Cancer 88: 163-166
17. Hayward JL, Rubens RD, Carbone PP, Heuson JC, Kumaoka S, Segaloff A (1977) Assessment of response to therapy in advanced breast cancer. Br J Cancer 35: 292-298
18. Klaassen U, Wilke H, Weyhofen R, Harstrick A, Eberhardt W, Muller C, Korn M, Hanske M, Diergarten K, Seeber S (1998) Phase II study with cisplatin and paclitaxel in combination with weekly high-dose 24 h infusional 5-fluorouracil/leucovorin for first-line treatment of metastatic breast cancer. Anticancer Drugs 9: 203-207
19. Kojima K, Nihei Z (1995) Expression of endothelin-1 immunoreactivity in breast cancer. Surg Oncol 4: 309-315
20. Kourembanas S, Marsden PA, McQuillan LP, Faller DV (1991) Hypoxia induces endothelin gene expression and secretion in cultured endothelium. J Clin Invest 88: 1054-1057
21. Levin ER (1995) Endothelins. N Engl J Med 333: 356-363
22. Nelson BJ, Chan-Tack K, Hedican SP, Magnuson SR, Opgenorth TJ, Bova GS, Simons JW (1996) Endothelin-1 production and decreased Endothelin B Receptor expression in advanced prostate cancer. Cancer Res 56: 663-668
23. Nelson JB, Carducci MA (1999) The role of the endothelin axis in prostate cancer. Prostate J 1: 126-130
24. Nelson J, Bagnato A, Battistini B, Nisen P (2003) The endothelin axis: emerging role in cancer. Nature Rev 3: 110-116
25. Pedram A, Rasandi M, Hu RM, Levin ER (1997) Vasoactive peptides modulate vascular endothelial cell growth factor production and endothelin cell proliferation and invasion. J Biol Chem 272: 17097-17103
26. Pirtskhalaishvili G, Nelson JB (2002) The endothelin receptor: a novel target for anticancer therapy. Am J Cancer 1: 1-7
27. Rosano L, Spinella F, Salani D, Di Castro V, Venuti A, Nicotra MR, Natali PG, Bagnato A (2003) Therapeutic targeting of the Endothelin A Receptor in Human Ovarian Carcinoma. Cancer Res 63: 2447-2453
28. Rosano L, Varmi M, Salani D, Di Castro V, Spinella F, Natali PG, Bagnato A (2001) Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells. Cancer Res 61: 8340-8346
29. Rubanji GM, Polokoff MA (1994) Endothelins: molecular biology, biochemistry, pharmacology, physiology and pathophysiology. Pharmacol Rev 46: 325-415
30. Salani D, Di Castro V, Nicotra MR, Rosano L, Tecce R, Venuti A, Natali PG, Bagnato A (2000) Role of Endothelin-1 in neovascularization of ovarian carcinoma. Am J Pathol 157: 1537-1547
31. Sinn HP, Schmid H, Junkermann H, Huober J, Leppien G, Kaufmann M, Bastert G, Otto HF (1994) Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy. Geburtshilfe Frauenheilkd 54: 552-558
32. Spinella F, Rosano L, DiCastro V, Natali PG, Bagnato A (2002) Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor 1α in ovarian cancer cells. J Biol Chem 277: 27850-27855
33. Vacca F, Bagnato A, Catt KJ, Tecce R (2000) Transactivation of the epidermal growth factor receptor in endothelin-1-induced mitogenic signaling in human ovarian carcinoma cells. Cancer Res 60: 5310-5317
34. Wülfing P, Diallo R, Kersting C, Wülfing C, Poremba C, Rody A, Greb RR, Böcker W, Kiesel L (2003) Expression of Endothelin-1, Endothelin-A and Endothelin-B Receptor in human breast cancer and correlation with long-term follow-up. Clin Cancer Res 9: 4125-4131
35. Yamashita J, Ogawa M, Inada K, Yamashita S, Matsuo S, Takano S (1991) A large amount of endothelin-1 is present in human breast cancer tissues. Res Commun Chem Pathol Pharmacol 74: 363-369
36. Yamashita J, Ogawa M, Sakai K (1995) Prognostic significance of three novel biologic factors in a clinical trial of adjuvant therapy for node-negative breast cancer. Surgery 117: 601-608
37. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kabayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki Y (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332: 411-415